{
    "nct_id": "NCT04635189",
    "official_title": "A Phase II Study of Steroid Sparing Treatment With Daratumumab and Lenalidomide in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma",
    "inclusion_criteria": "* Diagnosis of multiple myeloma with diagnosis\n* Must not have received previous therapy for multiple myeloma\n* Newly diagnosed and not considered candidate for high-dose chemotherapy\n* Adequate organ system function\n* A performance status ≤ 3\n* Ability to swallow and retain oral medication\n* Female subjects of child bearing potential must be surgically sterile, be post-menopausal\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* A diagnosis of primary amyloidosis; monoclonal gammopathy of undetermined significance, smoldering multiple myeloma; non-secretory myeloma\n* A diagnosis of Waldenström's disease\n* Receiving cancer therapy\n* Radiation therapy within 14 days of enrollment\n* Major surgery within 2 weeks before enrollment\n* Human immunodeficiency virus -infected patients must be on effective anti-retroviral therapy with undetectable viral load within the past 6 months\n* Seropositive for hepatitis B, or seropositive for hepatitis C\n* Ongoing systemic bacterial, fungal or viral infection\n* Severe and/or uncontrolled medical conditions\n* Malignancy within 2 years of study enrollment\n* Women who are pregnant or lactating\n* Contraindications to required prophylaxis for deep vein thrombosis and pulmonary embolism.",
    "miscellaneous_criteria": ""
}